All Posts Tagged With: "UTHR"
(GILD) Gilead Sciences Terminates Letairis Phase III Trial
Gilead Sciences Inc.(GILD) recently announced that it will terminate its phase III trial (ARTEMIS-IPF) studying Letairis (ambrisentan) for the treatment of idiopathic pulmonary fibrosis (IPF) due to lack...
(UTHR) United Therapeutics Beats Expectations on Strong Revenues
United Therapeutics Corp. (UTHR) reported first-quarter profit of 32 cents per share, a couple of cents above the Zacks Consensus Estimate and 28% above the year-ago earnings of 25 cents. A huge boost in...
(UTHR) United Therapeutics Corporation Misses Earnings Estimates
United Therapeutics Corporation (UTHR) reported a net income of 21 cents per share in the third quarter, well below the Zacks Consensus Estimate of 31 cents. The company reported earnings of 22 cents in the...